Role of Endocannabinoid System in Mental Diseases

Overview

Journal Neurotox Res

Publisher Springer

Specialty Neurology

Date 2004 Aug 25

PMID 15325960

Citations 22

Authors

Jorge Manzanares

Leyre Uriguen

Gabriel Rubio

Tomas Palomo

Affiliations

Soon will be listed here.

Abstract

In the last decade, a large number of studies using Delta9-tetrahydrocannabinol (THC), the main active principle derivative of the marijuana plant, or cannabinoid synthetic derivatives have substantially contributed to advance the understanding of the pharmacology and neurobiological mechanisms produced by cannabinoid receptor activation. Cannabis has been historically used to relieve some of the symptoms associated with central nervous system disorders. Nowadays, there are anecdotal evidences for the use of cannabis in many patients suffering from multiple sclerosis or chronic pain. Following the historical reports of the use of cannabis for medicinal purposes, recent research has highlighted the potential of cannabinoids to treat a wide variety of clinical disorders. Some of these disorders that are being investigated are pain, motor dysfunctions or psychiatric illness. On the other hand, cannabis abuse has been related to several psychiatric disorders such as dependence, anxiety, depression, cognitive impairment, and psychosis. Considering that cannabis or cannabinoid pharmaceutical preparations may no longer be exclusively recreational drugs but may also present potential therapeutic uses, it has become of great interest to analyze the neurobiological and behavioral consequences of their administration. This review attempts to link current understanding of the basic neurobiology of the endocannabinoid system to novel opportunities for therapeutic intervention and its effects on the central nervous system.

Citing Articles

Cannabis and Anxiety: A Critical Review.

Beletsky A, Liu C, Lochte B, Samuel N, Grant I Med Cannabis Cannabinoids. 2024; 7(1):19-30.

PMID: 38406383 PMC: 10890807. DOI: 10.1159/000534855.

Integrating Endocannabinoid Signalling In Depression.

Rana T, Behl T, Sehgal A, Mehta V, Singh S, Kumar R J Mol Neurosci. 2021; 71(10):2022-2034.

PMID: 33471311 DOI: 10.1007/s12031-020-01774-7.

A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve Its Effectivess on Neuronal Aging.

Morsanuto V, Galla R, Molinari C, Uberti F Brain Sci. 2020; 10(7).

PMID: 32708932 PMC: 7408069. DOI: 10.3390/brainsci10070457.

Endocannabinoid System Components as Potential Biomarkers in Psychiatry.

Navarrete F, Garcia-Gutierrez M, Jurado-Barba R, Rubio G, Gasparyan A, Austrich-Olivares A Front Psychiatry. 2020; 11:315.

PMID: 32395111 PMC: 7197485. DOI: 10.3389/fpsyt.2020.00315.

Noradrenergic depletion causes sex specific alterations in the endocannabinoid system in the Murine prefrontal cortex.

Urquhart M, Ross J, Reyes B, Nitikman M, Thomas S, Mackie K Neurobiol Stress. 2019; 10:100164.

PMID: 31193575 PMC: 6535650. DOI: 10.1016/j.ynstr.2019.100164.

References

Beltramo M, Stella N, Calignano A, Lin S, Makriyannis A, Piomelli D . Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997; 277(5329):1094-7. DOI: 10.1126/science.277.5329.1094. View

Koob G . Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992; 13(5):177-84. DOI: 10.1016/0165-6147(92)90060-j. View

Matsuda L, Lolait S, Brownstein M, Young A, Bonner T . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284):561-4. DOI: 10.1038/346561a0. View

Zimmer A, Zimmer A, Hohmann A, Herkenham M, Bonner T . Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999; 96(10):5780-5. PMC: 21937. DOI: 10.1073/pnas.96.10.5780. View

Hanus L, Fride E, Breuer A, Vogel Z, Shalev D, Kustanovich I . 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001; 98(7):3662-5. PMC: 31108. DOI: 10.1073/pnas.061029898. View

Navarro M, Hernandez E, Munoz R, Del Arco I, Villanua M, Carrera M . Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 1997; 8(2):491-6. DOI: 10.1097/00001756-199701200-00023. View

Cravatt B, Demarest K, Patricelli M, Bracey M, Giang D, Martin B . Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98(16):9371-6. PMC: 55427. DOI: 10.1073/pnas.161191698. View

Thomas H . Psychiatric symptoms in cannabis users. Br J Psychiatry. 1993; 163:141-9. DOI: 10.1192/bjp.163.2.141. View

Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J . Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology. 2004; 46(7):966-73. DOI: 10.1016/j.neuropharm.2004.01.003. View

10.

Bovasso G . Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry. 2001; 158(12):2033-7. DOI: 10.1176/appi.ajp.158.12.2033. View

11.

Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E . Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000; 361(1):19-24. DOI: 10.1007/s002109900147. View

12.

Voruganti L, Slomka P, Zabel P, Mattar A, Awad A . Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001; 107(3):173-7. DOI: 10.1016/s0925-4927(01)00104-4. View

13.

Fuentes J, Ruiz-Gayo M, Manzanares J, Vela G, Reche I, Corchero J . Cannabinoids as potential new analgesics. Life Sci. 1999; 65(6-7):675-85. DOI: 10.1016/s0024-3205(99)00290-8. View

14.

Kouri E, Pope Jr H, Lukas S . Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology (Berl). 1999; 143(3):302-8. DOI: 10.1007/s002130050951. View

15.

Wickelgren I . Marijuana: harder than thought?. Science. 1997; 276(5321):1967-8. DOI: 10.1126/science.276.5321.1967. View

16.

Johns A . Psychiatric effects of cannabis. Br J Psychiatry. 2001; 178:116-22. DOI: 10.1192/bjp.178.2.116. View

17.

Swift W, Hall W, Teesson M . Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction. 2001; 96(5):737-48. DOI: 10.1046/j.1360-0443.2001.9657379.x. View

18.

Iversen L, Chapman V . Cannabinoids: a real prospect for pain relief?. Curr Opin Pharmacol. 2002; 2(1):50-5. DOI: 10.1016/s1471-4892(01)00120-5. View

19.

Lastres-Becker I, Gomez M, de Miguel R, Ramos J, Fernandez-Ruiz J . Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotox Res. 2003; 4(7-8):601-608. DOI: 10.1080/10298420290030514. View

20.

McGee R, Williams S, Poulton R, Moffitt T . A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction. 2000; 95(4):491-503. DOI: 10.1046/j.1360-0443.2000.9544912.x. View